Stockscreener 앱 받기
0.6408
0.79%
0.0041
전일 마감가:
$0.6367
열려 있는:
$0.65
하루 거래량:
67,649
Relative Volume:
0.09
시가총액:
$25.52M
수익:
$1.04M
순이익/손실:
$-67.50M
주가수익비율:
-0.3334
EPS:
-1.9222
순현금흐름:
$-60.67M
1주 성능:
+0.30%
1개월 성능:
+12.32%
6개월 성능:
-85.87%
1년 성능:
-73.59%
1일 변동 폭
$0.638
$0.65
1주일 범위
$0.6194
$0.6759
52주 변동 폭
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6441 | 25.23M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.42 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
826.50 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.43 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.09 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Investor meetings as Vistagen joins Jefferies 2026 healthcare event in NYC - Stock Titan
Vistagen Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Vistagen Therapeutics (VTGN) Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesExpert Market Insights - Newser
VTGN Stock Price, Quote & Chart | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
VistaGen Appoints New Chief Medical Officer to Advance Pipeline - The Globe and Mail
VTGN: Fasedienol nears pivotal phase III data in SAD, with pipeline progress and cash runway into 2027 - TradingView
[Form 4] Vistagen Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 3] Vistagen Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vistagen (VTGN) hires Angel S. Angelov, MD, MBA as Chief Medical Officer with option grant - Stock Titan
VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen appoints Angel S. Angelov as chief medical officer - marketscreener.com
Vistagen appoints Angel Angelov as chief medical officer By Investing.com - Investing.com Australia
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer - Yahoo Finance
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - Insider Monkey
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
[SCHEDULE 13G/A] Vistagen Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
All News about Vistagen Therapeutics, Inc.Common Stock - The Chronicle-Journal
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - marketscreener.com
Vistagen Therapeutics, Inc.Common Stock (NQ: VTGN - FinancialContent
Vistagen Reports Positive 12-Month Data for Fasedienol Nasal Spray in Social Anxiety Disorder Phase 3 Trial - Minichart
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Vistagen (VTGN) Reports Positive Data from Fasedienol Study for Social Anxiety - GuruFocus
VistaGen Reports Positive Long-Term Data for Fasedienol - TipRanks
Vistagen announces preliminary positive data in ongoing open-label extension portion of PALISADE-3 phase 3 study of fasedienol for the acute treatment of social anxiety disorder - marketscreener.com
Vistagen announces positive OLE safety and 4-month efficacy signals for fasedienol in social anxiety - TradingView
Vistagen (NASDAQ: VTGN) reports positive PALISADE-3 OLE results - Stock Titan
Vistagen reports preliminary data from social anxiety trial By Investing.com - Investing.com Canada
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - marketscreener.com
TradingKey - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-05-10 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Trial of Fasedienol Nasal Spray for Social Anxiety Disorder; Topline Results Expected Q2 2026 - Minichart
ex_558852.htm - SEC.gov
Vistagen (VTGN) completes PALISADE-4 randomized phase, eyes Q2 2026 data - Stock Titan
Vistagen (VTGN) Wraps Up Final Patient Visits in Phase 3 Anxiety Trial - GuruFocus
Vistagen completes enrollment in phase 3 anxiety trial By Investing.com - Investing.com Canada
Public-speaking challenge study ends; Vistagen data due this quarter - Stock Titan
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire
2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect | NDAQ:VTGN | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) S - The National Law Review
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Vistagen (VTGN) wins FDA go-ahead to advance refisolone Phase 2 hot flash studies - Stock Titan
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe
VistaGen appoints Nick Tressler as CFO - MSN
VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
1.91%
자본화:
|
볼륨(24시간):